Trump Marijuana Reforms: Executive Order Signed, Advancing Research and Medicare Access

Following initial reports of its intent, President Trump signed an executive order on December 19, 2025, easing federal marijuana restrictions for medical use. It directs reclassification from Schedule I, expands research, supports cannabis treatments, and enables Medicare coverage—stopping short of recreational legalization.

President Donald Trump signed the executive order on December 19, 2025, as reported by NPR's Brian Mann, building on Thursday's announcement. The measure directs the attorney general to advance reclassifying marijuana from Schedule I (high abuse, no medical use) to Schedule III (accepted medical uses, lower risk), alongside drugs like ketamine.

Key provisions expand research into marijuana's benefits, facilitate medical treatments for conditions like chronic pain, and remove barriers for Medicare to fund cannabis-based therapies, including some CBD products from hemp. Trump noted, 'We have people begging me to do this, people who have been suffering for decades.'

While states lead on legalization, this federal step could boost the cannabis industry by easing banking and research hurdles, as seen in rising stock prices post-announcement. It balances reform advocates' demands with caution amid political divides, maintaining federal controls and penalties.

Awọn iroyin ti o ni ibatan

Illustration of Anvisa approving medical cannabis cultivation in Brazil, featuring scientists in a lab with plants and official documents.
Àwòrán tí AI ṣe

Anvisa approves cannabis cultivation for medical purposes

Ti AI ṣe iroyin Àwòrán tí AI ṣe

The National Health Surveillance Agency (Anvisa) approved, on January 28, 2026, resolutions allowing cannabis cultivation for health treatments and research, along with new administration routes and plant imports. This step marks progress in the national production chain, easing access to plant-derived medicines. The changes broaden options for patients with severe illnesses while upholding strict restrictions.

US President Donald Trump signed an executive order recommending the easing of federal marijuana regulations, a potentially significant shift in the country's drug policy. The measure directs the attorney general to advance reclassification of the drug, possibly moving it from Schedule I to Schedule III. The decision aims to boost medical research and could affect the cannabis industry, though marijuana would remain federally illegal.

Ti AI ṣe iroyin

In his first year back in the White House, President Trump has overhauled US drug policy, abandoning the Biden administration's public health strategies in favor of aggressive military actions against fentanyl trafficking. Experts warn that these changes, including deep cuts to treatment programs, could reverse recent declines in overdose deaths. The pivot includes designating fentanyl as a weapon of mass destruction and launching naval strikes on suspected drug boats.

In an RND interview, Federal Medical Association President Klaus Reinhardt discusses Germany's high doctor visit rates, which he does not attribute solely to patient behavior. He warns against planned prescribing rights for pharmacists and advocates for a sugar tax as well as smartphone bans in schools. Additionally, he supports a new regulation of assisted suicide with strict protective measures.

Ti AI ṣe iroyin

At the World Economic Forum in Davos, US President Donald Trump pledged to sign sweeping cryptocurrency market structure legislation very soon, aiming to keep America as the crypto capital of the world. He framed the push as essential to outpace China in financial innovation. The remarks come amid bitcoin's surge above $90,000 and strong political support from the crypto industry.

In 2025, widespread opposition challenged President Trump's policies through street protests, electoral victories, and court rulings. Approval ratings for Trump dropped sharply amid economic struggles and controversial deportations. Legal experts highlight over 150 federal court blocks on his executive actions, though the Supreme Court offered mixed support.

Ti AI ṣe iroyin

President Donald Trump has announced plans for executive action to prevent large institutional investors from purchasing single-family homes in the United States. The move addresses concerns over housing affordability amid high inflation. He urged Congress to make the policy permanent through legislation.

 

 

 

Ojú-ìwé yìí nlo kuki

A nlo kuki fun itupalẹ lati mu ilọsiwaju wa. Ka ìlànà àṣírí wa fun alaye siwaju sii.
Kọ